News

Informed discussions about the pros and cons of different treatments help guide the decision-making process. When it comes to treatment adherence and overall quality of life, patient lifestyle plays a significant role.

This new data demonstrated that hearing loss led to worse outcomes for older individuals, and fatigue assessments may be needed in the future to further capture fatigue’s multidimensionality.

Each month, our editorial staff compiles a recap of the top news in ophthalmology from the past month. Our June 2023 month-in-review features updates to the pipeline, diabetic eye disease news from ADA 2023, and promising data on the use of artificial intelligence.

The biosimilar month in review highlights ranibizumab biosimilars for the treatment of nAMD, Optum Rx’s decision to recognize subcutaneous adalimumab-adbm as a preferred brand, and the cost-saving benefits of biosimilars for patients.

An analysis from ADA 2023 suggests adults with T1D and higher social determinants of health risks are less likely to perform behaviors to maintain health.

There were several individual predictors including sex, age, recent visits with a primary care provider, distance to nearest endoscopy facility, and insurance type, as well as county-level predictors, such as percentage of residents with a high school education, without insurance, and unemployed as being up-to-date.

A cascade-of-clearance study from the CDC shows the country is far from its goal of eliminating 80% of hepatitis C cases by 2030.

In these preliminary results from the ongoing POSITIVE study, tildrakizumab was shown to have led to significant improvement for psoriasis patients.

The reported C difficile healthcare-acquired infections rates per 10,000 patient days did not significantly change. The rates were 8.07 in the 6-month preintervention period and 8.77 in the intervention period for facilities A and B combined.

Both biologic-naïve and biologic-experience patients saw benefits in the BRIGHT study examining therapeutic response to brodalumab over the course of 1 year.

The AHEAD program was associated with promising reductions in mean diabetes distress scores among emerging adults with type 1 diabetes.

A combination of in-office and telehealth visits increased visit frequency and maintained glycemic control in older adults with T1D during the COVID-19 pandemic.

The threshold values for the SOF/VEL prophylaxis strategies showed that the 4-week strategy likely won’t be less costly under any reasonable value of the input variables.

New data on oral immunotherapy to food allergens shows promise for the treatment, though more information with standard interventions and regimens is needed to gain certainty on the efficacy and safety.

Julie Heverly, of the Time in Range Coalition, discusses the history of time in range, offers perspective on its utility as a glucose metric, and provides an overview of the efforts of the Time in Range Coalition to advance use and education around time in range.

There were higher percentages of patients treated with mirikizumab that had clinical remission at week 12 of the induction trial compared to the placebo group. This was also true at week 40 of the maintenance trial.

New late-breaking phase 3 data showed success with nemolizumab, an investigational drug designed for targeting IL-31 signaling and aimed at the underlying causes of the condition.

An analysis of data from nearly 750,000 adolescents from more than 40 countries offers insight into the changing, and possibly inaccurate, perceptions of healthy body weight among younger people since the turn of the century.

The citrate-free high-concentration formulation and citrate-containing low-concentration of biosimilar adalimumab-bwwd are now available to patients living in the US.

From a novel acne cream to a breakthrough depression drug, a half-dozen agent decisions are coming through in the coming 6 months.

Unacceptable pain is a significant problem for some patients with rheumatoid arthritis, but what proportion of patients are affected? Test your knowledge with this quiz.

Dr. Juliana Biondo discusses what the future of treatment for hemophilia A looks like based on ongoing trials.

New clinical trial data shows benefits of spesolimab for GPP flares, providing compelling evidence for IL-36 signaling’s effect on the condition’s pathogenesis.

This endocrine case report from Brady Pregerson, MD, features a man in his 60s with diabetes mellitus presenting with 5 days of nonradiating intermittent lower abdominal pain. Can you determine the correct diagnosis?

Headache, pruritis, fatigue, eosinophilia, injection-site reactions, upper abdominal pain, arthralgia, and asthenia were more common in the bulevirtide group compared to the control group.

This cardiology case report from Brady Pregerson, MD, features a man in his late 80s presenting to urgent care with multiple episodes of near syncope in the past 3 days. Check out the ECG and determine the correct diagnosis!

New data indicates that hospital culture must be considered when facilities make significant changes, especially when they concern institutional values.